Moderna’sChief medical officer stated on Sunday that the vaccine company offers for children younger than 6 years of age. The panel from Food and Drug Administration will review it when they meet in June.

Moderna applied for an FDA emergency use authorization on Thursday.

To review the request, a panel of advisors to the U.S. regulator for drugs will meet in June.

“I believe that the FDA now has the essential data necessary to allow them to review applications. In an interview on CBS’ Face the Nation, Dr. Paul Burton, the chief medical officer of the company, stated that “Yes, we are very confident.”

Moderna could become the first vaccine to be approved for U.S. children younger than 5. PfizerIt also anticipates that its data on vaccines for children below 6 years old will be available by June’s review.

Burton commented that “the safety profile in vaccines for the very youngest children has been very reassuring” – there are actually lower rates of safety events than in 6-year olds or 12-year olds. That’s fantastic.

The FDA has approved Moderna’s vaccine for adults over 18 years. The FDA has not yet approved the vaccine for children aged 6-17 years in the United States, even though it was approved for such a age in Australia and Canada. The U.S. regulatory authorities have requested more safety data from the company.

Burton announced that Burton believes that another booster shot will be tested by Burton. He said this on Sunday. The booster shots will target both the Beta variant and the original coronavirus.

Moderna anticipates having large quantities of the new vaccine booster by fall for protection against Omicron, and other Covid-19 variants.